December 15th, 2015

Company Update (NASDAQ:BIIB): Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII

[Marketwired] – Amunix Operating Inc. announced today that Biogen Idec has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products … Read . . . → Read More: Company Update (NASDAQ:BIIB): Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII Similar Articles: Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting Stock Update (NASDAQ:BIIB): Biogen Idec to Report First Quarter 2014 Financial Results on April 23, 2014 Company Update: Biogen Idec Inc (NASDAQ:BIIB) – U.S. FDA approves Biogen’s hemophilia B drug Alprolix
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.